Genexpath

Genexpath was born from the desire of researchers to see their research benefit to the greatest number and to allow practitioners to effectively refine their analyzes. This research work is therefore now accessible to pathologists and molecular biologists all over the world. Genexpath develops, produces and commercializes tumor classification tests designed to meet the needs of professionals involved in patient diagnosis and treatment. The tests are based on an innovative technique which has been the subject of several publications in high-impact scientific journals, and has generated four patent applications. These tests are performed on tumor RNA biopsied from the patient. The innovation lies in the fact that the quantity of RNA required is very small, and that in the case of sarcoma, a less invasive needle biopsy is sufficient to detect fusion transcripts (chromosomal abnormality). Genexpath kits allow much faster and much cheaper analysis than traditional methods.